CANbridge Files to Start China Trials of Esophageal Cancer Treatment

CANbridge Life Sciences, a Beijing biopharma, filed an IND application to the CFDA for a Phase Ib/III trial of CAN017 in esophageal squamous cell cancer (ESCC). Founded in 2012, CANbridge develops western drugs for China and North Asia . The company in-licensed rights to CAN017 in 2016 from Aveo Oncology of Massachusetts in a $134 million agreement. The IND is CANbridge’s second CFDA submission in 2017; it filed an IND for its lead candidate, CAN008, for glioblastoma, in July. More details.... Stock Symbol: (NSDQ: AVEO ) Share this with colleagues: // //